8-K: Paid, Inc. Extends Embolx Loan Again Amidst Defaults

Paid, Inc. has further extended the forbearance agreement with Embolx, Inc. for a secured convertible note, now through October 31, 2026, following multiple previous defaults and modifications.

Summary

• Paid, Inc. has entered into a series of agreements with Embolx, Inc. concerning a secured convertible note originally issued on October 13, 2022.
• The note has experienced multiple defaults, with the latest forbearance agreement extending the maturity date to October 31, 2026.
• The total outstanding balance, referred to as the Default Balance, has increased significantly, reaching $6,956,168 as of September 30, 2025.
• A new investment of $687,500 was made, increasing the principal amount to $916,664 due to an original issue discount.
• Embolx, Inc. is required to provide updated proxies from its shareholders to Paid, Inc. by October 31, 2026, to maintain the forbearance.
• Failure to provide these proxies by the deadline will result in a 20% default penalty on the outstanding balance and trigger other remedies for Paid, Inc.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to ongoing defaults and repeated extensions of loan maturity dates, indicating significant financial distress for Embolx, Inc. and potential recovery challenges for Paid, Inc.

Positives

• Paid, Inc. has secured a further extension of the forbearance agreement, providing additional time for Embolx, Inc. to resolve its obligations.
• The company has received updated proxies from Embolx, Inc. shareholders, indicating continued, albeit conditional, support.
• The agreement outlines specific conditions for the extension, including the delivery of signed proxies by a set deadline.

Negatives

• Embolx, Inc. has been in default on its obligations multiple times since the original note issuance in October 2022.
• The total Default Balance has escalated to $6,956,168 as of September 30, 2025, from an initial $1,875,000 note.
• The latest extension is contingent on Embolx, Inc. providing updated shareholder proxies by October 31, 2026, with failure resulting in a 20% penalty.
• The repeated need for forbearance and loan modifications suggests ongoing financial instability at Embolx, Inc.

Risks

• Risk of a 20% default penalty being applied to the Default Balance if Embolx, Inc. fails to deliver signed proxies by October 31, 2026.
• Potential for further defaults or inability of Embolx, Inc. to meet its obligations even with the extended deadline.
• The security interest in Embolx, Inc.'s assets may not be sufficient to recover the full outstanding debt in the event of a final default.
• The value of the convertible note and potential equity conversion is subject to the performance and valuation of Embolx, Inc.

Future Outlook

The future outlook is uncertain and heavily dependent on Embolx, Inc.'s ability to meet the conditions of the extended forbearance agreement, specifically the delivery of signed shareholder proxies by October 31, 2026. Failure to do so will result in a significant penalty and potential acceleration of remedies for Paid, Inc.

Management Comments

• Company acknowledges default of obligations under the Loan Documents.
• Company has requested Holder to forbear from exercising rights and remedies as a result of the Default and to modify obligations.
• Company affirms and restates representations and warranties contained in the Loan Documents.
• Company agrees to promptly execute and deliver documents requested by Holder to effectuate the Agreement.
• Company represents and warrants that all necessary actions have been taken for the execution, delivery, and performance of the Agreement.

Industry Context

StockSavvy.ai notes that this situation highlights the risks associated with venture debt and distressed investments, particularly in early-stage or struggling companies. The repeated defaults and extensions suggest a challenging operating environment for Embolx, Inc. and a protracted recovery process for Paid, Inc.

Comparison to Industry Standards

• Industry standards for venture debt typically involve clear repayment schedules and covenants. The repeated defaults and modifications in this case suggest Embolx, Inc. is not meeting these standards.
• Forbearance agreements are common in distressed situations, but the frequency and magnitude of extensions in this scenario are notable.
• The inclusion of original issue discounts and warrants is standard practice in venture debt to compensate for higher risk, but the escalating default balance indicates the risk has materialized significantly.
• Companies like Silver Lake or KKR, which engage in private credit, often have more robust due diligence and workout processes, but even they face challenges with deeply distressed borrowers.

Stakeholder Impact

• Shareholders of Paid, Inc.: Potential for delayed or partial recovery of investment in Embolx, Inc. due to ongoing defaults and extensions. The value of the convertible note is at risk.
• Shareholders of Embolx, Inc.: The continued financial strain on Embolx, Inc. due to debt obligations could impact future growth and equity value.
• Creditors of Embolx, Inc.: The secured position of Paid, Inc. may affect the recovery prospects for other creditors if Embolx, Inc. defaults further.

Next Steps

• Embolx, Inc. must deliver signed proxies representing a majority of each class of shareholders by October 31, 2026.
• If proxies are delivered, the forbearance agreement continues through October 31, 2026.
• If proxies are not delivered, a 20% default penalty will be applied to the Default Balance, and Paid, Inc. can pursue all rights and remedies.
• Paid, Inc. will continue to monitor Embolx, Inc.'s compliance with the terms of the modified loan documents.

Key Dates

Recommendation

The situation presents significant risk due to Embolx, Inc.'s repeated defaults and the increasing debt burden. While Paid, Inc. has secured extensions and a potential penalty, the ultimate recovery is uncertain. A 'hold' recommendation reflects the speculative nature of the investment and the need for further clarity on Embolx, Inc.'s ability to meet its obligations.

Keywords

forbearance agreement, loan modification, convertible note, default, extension, secured note, Embolx, Paid, Inc.